RP-6306

Phase 2Small molecule

DDebiopharm International SA

RP-6306 is one of 36 small molecule programs targeting Uterine Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine CancerActive, not recruiting

Breast CancerRecruiting

Uterine CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

RP-6306

DDebiopharm International SA

Phase 2

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Ablavar

LLantheus Medical Imaging

Preclinical

2 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT05601440

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Terminated·DDebiopharm International SA·Phase 1·NCT05147350·38 enrolled

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Terminated·DDebiopharm International SA·Phase 1·NCT05147272·67 enrolled

Uterine Cancer1 trial

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06107868·6 enrolled

Advanced Cancer1 trial

RP-6306 in Patients With Advanced Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT05605509·28 enrolled

Breast Cancer1 trial

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05601440·484 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for RP-6306. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RP-6306 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RP-6306. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDebiopharm International SA

RP-6306

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Uterine Cancer1 trial

Advanced Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News